Viracta Therapeutics

Viracta Therapeutics Inc is a precision oncology company, focused on the development of new medicines targeting virus-associated malignancies. The company is conducting three clinical trials for its combination product candidate as a potential therapy for the treatment of relapsed/refractory Epstein-Barr virus-positive lymphoma. The product candidate of the company is a combination product candidate consisting of nanatinostat, a potent and selective small molecule inhibitor of class I histone deacetylases (HDAC), and valganciclovir, an FDA-approved anti-viral drug used to treat and prevent disease caused by a virus called cytomegalovirus (CMV) in people with organ transplants.

Movers_Stocks

ANNA

BHAT

CURV

EVTV

FCUV

GHRS

KRNT

PITA

PMNT

REBN

SBXD

SHEN

SSYS

UOKA

VIRX

WMPN

Why Triumph Group Shares Are Trading Higher By Over 36%; Here Are 20 Stocks Moving Premarket

benzinga_deal_dispatch2

Asset Sales

Legal

AMPS

BABA

BIGGQ

COEP

CPNG

Unlike Party City and Big Lots, The Container Store is staying in business. Plus, an oncology company searches for a deal.

Deal Dispatch: Party City Wraps Up, Big Lots Goes Bust, The Container Store Continues

Wall Street

Long Ideas

News

Pre-Market Outlook

Markets

Trading Ideas

AREN

EVAX

GDYN

GEAR

Castellum, Viracta Therapeutics And 3 Stocks To Watch Heading Into Friday (CORRECTED)

VIRACTA THERAPEUTICS INC by Viracta Therapeutics, Inc.

Viracta Therapeutics Inc

Earnings

Press Releases

Viracta Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update

Management

Viracta Therapeutics Appoints Michael Faerm as Chief Financial Officer

Viracta Therapeutics Announces New Employment Inducement Grants

Viracta Therapeutics Announces Positive Data from the Phase 2 NAVAL-1 Trial, Regulatory Progress, and Updated Nana-val Clinical Development Plan

Viracta Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update

Viracta Therapeutics to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Viracta Therapeutics Announces Reprioritization of Resources to Enhance Focus on Nana-val Development Program in Patients with Relapsed or Refractory EBV-Positive Peripheral T-Cell Lymphoma

Viracta Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update

Health Care

Viracta Therapeutics Announces Closure of NAVAL-1 Clinical Trial and Exploration of Strategic Alternatives

Comments

Viracta Therapeutics

Connect With Us

About Benzinga

Market Resources

Trading Tools & Education

Ring the Bell